Search

Your search keyword '"Hellawell, Giles"' showing total 161 results
Start Over Author "Hellawell, Giles"
161 results on '"Hellawell, Giles"'

2. Developing a Diagnostic Multivariable Prediction Model for Urinary Tract Cancer in Patients Referred with Haematuria: Results from the IDENTIFY Collaborative Study

Author

Chaudry, Aasem, Sharma, Abhishek, Bennett, Adam, Ahmad, Adnan, Abroaf, Ahmed, Suliman, Ahmed Musa, Lloyd, Aimee, McKay, Alastair, Wong, Albert, Silva, Alberto, Schneider, Alexandre, MacKay, Alison, Knight, Allen, Grigorakis, Alkiviadis, Bdesha, Amar, Nagle, Amy, Cebola, Ana, Dhanasekaran, Ananda Kumar, Kondža, Andraž, Barcelos, André, Galosi, Andrea Benedetto, Ebur, Andrea, Minervini, Andrea, Russell, Andrew, Webb, Andrew, de Jalón, Ángel García, Desai, Ankit, Czech, Anna Katarzyna, Mainwaring, Anna, Adimonye, Anthony, Das, Arighno, Figueiredo, Arnaldo, Villers, Arnauld, Leminski, Artur, Chippagiri, Arvinda, Lal, Asim Ahmed, Yıldırım, Asıf, Voulgaris, Athanasios Marios, Uzan, Audrey, Oo, Aye Moh Moh, Younis, Ayman, Zelhof, Bachar, Mukhtar, Bashir, Ayres, Ben, Challacombe, Ben, Sherwood, Benedict, Ristau, Benjamin, Lai, Billy, Nellensteijn, Brechtje, Schreiter, Brielle, Trombetta, Carlo, Dowling, Catherine, Hobbs, Catherine, Benitez, Cayo Augusto Estigarribia, Lebacle, Cédric, Ho, Cherrie Wing Yin, Ng, Chi-Fai, Mount, Chloe, Lam, Chon Meng, Blick, Chris, Brown, Christian, Gallegos, Christopher, Higgs, Claire, Browne, Clíodhna, McCann, Conor, Plaza Alonso, Cristina, Beder, Daniel, Cohen, Daniel, Gordon, Daniel, Wilby, Daniel, Gordon, Danny, Hrouda, David, Lau, David Hua Wu, Karsza, Dávid, Mak, David, Martin-Way, David, Suthaharan, Denula, Patel, Dhruv, Carrion, Diego M, Nyanhongo, Donald, Bass, Edward, Mains, Edward, Chau, Edwin, Canelon Castillo, Elba, Day, Elizabeth, Desouky, Elsayed, Gaines, Emily, Papworth, Emma, Yuruk, Emrah, Kilic, Enes, Dinneen, Eoin, Palagonia, Erika, Xylinas, Evanguelos, Khawaja, Faizan, Cimarra, Fernando, Bardet, Florian, Kum, Francesca, Peters, Francesca, Kovács, Gábor, Tanasescu, Geroge, Hellawell, Giles, Tasso, Giovanni, Lam, Gitte, La Montagna, Giuseppe, Pizzuto, Giuseppe, Lenart, Gordan, MacLennan, Graeme, Özgür, Günal, Bi, Hai, Lyons, Hannah, Warren, Hannah, Ahmed, Hashim, Simpson, Helen, Burden, Helena, Gresty, Helena, Rios Pita, Hernado, Clarke, Holly, Serag, Hosam, Kynaston, Howard, Crawford-Smith, Hugh, Mostafid, Hugh, Otaola-Arca, Hugo, Koo, Hui Fen, Ibrahim, Ibrahim, Ouzaid, Idir, Puche-Sanz, Ignacio, Tomašković, Igor, Tinay, Ilker, Sahibzada, Iqbal, Thangasamy, Isaac, Cadena, Iván Revelo, Irani, Jacques, Udzik, Jakub, Brittain, James, Catto, James, Green, James, Tweedle, James, Hernando, Jamie Borrego, Leask, Jamie, Kalsi, Jas, Frankel, Jason, Toniolo, Jason, Raman, Jay D., Courcier, Jean, Kumaradeevan, Jeevan, Clark, Jennifer, Jones, Jennifer, Teoh, Jeremy Yuen-Chun, Iacovou, John, Kelly, John, Selph, John P., Aning, Jonathan, Deeks, Jon, Cobley, Jonathan, Olivier, Jonathan, Maw, Jonny, Herranz-Yagüe, José Antonio, Nolazco, Jose Ignacio, Cózar-Olmo, Jose Manuel, Bagley, Joseph, Jelski, Joseph, Norris, Joseph, Testa, Joseph, Meeks, Joshua, Hernandez, Juan, Vásquez, Juan Luis, Randhawa, Karen, Dhera, Karishma, Gronostaj, Katarzyna, Houlton, Kathleen, Lehman, Kathleen, Gillams, Kathryn, Adasonla, Kelvin, Brown, Kevin, Murtagh, Kevin, Mistry, Kiki, Davenport, Kim, Kitamura, Kosuke, Derbyshire, Laura, Clarke, Laurence, Morton, Lawrie, Martinez, Levin, Goldsmith, Louise, Paramore, Louise, Cormier, Luc, Dell'Atti, Lucio, Simmons, Lucy, Martinez-Piñeiro, Luis, Rico, Luis, Chan, Luke, Forster, Luke, Ma, Lulin, Moore, Madeline, Gallego, Maria Camacho, Freire, Maria José, Emberton, Mark, Feneley, Mark, Antón-Juanilla, Marta, Rivero, Marta Viridiana Muñoz, Pirša, Matea, Tallè, Matteo, Crockett, Matthew, Liew, Matthew, Trail, Matthew, Peters, Max, Cooper, Meghan, Kulkarni, Meghana, Ager, Michael, He, Ming, Li, Mo, Omran Breish, Mohamed, Tarin, Mohamed, Aldiwani, Mohammed, Matanhelia, Mudit, Pasha, Muhammad, Akalın, Mustafa Kaan, Abdullah, Nasreen, Hale, Nathan, Gadiyar, Neha, Kocher, Neil, Bullock, Nicholas, Campain, Nicholas, Pavan, Nicola, Al-Ibraheem, Nihad, Bhatt, Nikita, Bedi, Nishant, Shrotri, Nitin, Lobo, Niyati, Balderas, Olga, Kouli, Omar, Capoun, Otakar, Oteo Manjavacas, Pablo, Gontero, Paolo, Mariappan, Paramananthan, Marchiñena, Patricio Garcia, Erotocritou, Paul, Sweeney, Paul, Planelles, Paula, Acher, Peter, Black, Peter C., Osei-Bonsu, Peter K, Østergren, Peter, Smith, Peter, Willemse, Peter-Paul Michiel, Chlosta, Piotr L., Ul Ain, Qurrat, Barratt, Rachel, Esler, Rachel, Khalid, Raihan, Hsu, Ray, Stamirowski, Remigiusz, Mangat, Reshma, Cruz, Ricardo, Ellis, Ricky, Adams, Robert, Hessell, Robert, Oomen, Robert J.A., McConkey, Robert, Ritchie, Robert, Jarimba, Roberto, Chahal, Rohit, Andres, Rosado Mario, Hawkins, Rosalyn, David, Rotimi, Manecksha, Rustom P., Agrawal, Sachin, Hamid, Syed Sami, Deem, Samuel, Goonewardene, Sanchia, Swami, Satchi Kuchibhotla, Hori, Satoshi, Khan, Shahid, Mohammud Inder, Shakeel, Sangaralingam, Shanthi, Marathe, Shekhar, Raveenthiran, Sheliyan, Horie, Shigeo, Sengupta, Shomik, Parson, Sian, Parker, Sidney, Hawlina, Simon, Williams, Simon, Mazzoli, Simone, Grzegorz Kata, Slawomir, Pinheiro Lopes, Sofia, Ramos, Sónia, Rai, Sonpreet, Rintoul-Hoad, Sophie, O'Meara, Sorcha, Morris, Steve, Turner, Stacey, Venturini, Stefano, Almpanis, Stephanos, Joniau, Steven, Jain, Sunjay, Mallett, Susan, Nikles, Sven, Shahzad, Yan, Sylvia, Lee, Taeweon, Uçar, Taha, Drake, Tamsin, Toma, Tarq, Cabañuz Plo, Teresa, Bonnin, Thierry, Muilwijk, Tim, Wollin, Tim, Chu, Timothy Shun Man, Appanna, Timson, Brophy, Tom, Ellul, Tom, Austin, Tomas, Smrkolj, Tomaž, Rowe, Tracey, Sukhu, Troy, Patel, Trushar, Garg, Tullika, Çaşkurlu, Turhan, Bele, Uros, Haroon, Usman, Crespo-Atín, Víctor, Parejo Cortes, Victor, Capapé Poves, Victoria, Gnanapragasam, Vincent, Gauhar, Vineet, During, Vinnie, Kumar, Vivek, Fiala, Vojtech, Mahmalji, Wasim, Lam, Wayne, Fung Chin, Yew, Filtekin, Yigit, Chyn Phan, Yih, Ibrahim, Youssed, Glaser, Zachary A, Abiddin, Zainal Adwin, Qin, Zijian, Zotter, Zsuzsanna, Zainuddin, Zulkifli, Khadhouri, Sinan, Gallagher, Kevin M., MacKenzie, Kenneth R., Shah, Taimur T., Gao, Chuanyu, Moore, Sacha, Zimmermann, Eleanor F., Edison, Eric, Jefferies, Matthew, Nambiar, Arjun, Anbarasan, Thineskrishna, Mannas, Miles P., Marra, Giancarlo, Gómez Rivas, Juan, Marcq, Gautier, Assmus, Mark A., Claps, Francesco, Boltri, Matteo, Burnhope, Tara, Nkwam, Nkwam, Boxall, Nicholas E., Downey, Alison P., Sukhu, Troy A., Chin, Yew-Fung, Green, James S.A., Goulao, Beatriz, Nielsen, Matthew, McGrath, John S., and Kasivisvanathan, Veeru

Published
2022
Full Text
View/download PDF

4. The European Urology Residents Education Programme Hands-on Training Format: 4 Years of Hands-on Training Improvements from the European School of Urology

Author

Somani, Bhaskar K., Van Cleynenbreugel, Ben, Gozen, Ali, Palou, Jaun, Barmoshe, Sas, Biyani, Shekhar, Gaya, Josep M., Hellawell, Giles, Pini, Giovannalberto, Oscar, Faba R., Sanchez Salas, Rafael, Macek, Petr, Skolarikos, Andreas, Wagner, Christian, Eret, Viktor, Haensel, Stephen, Siena, Giampaolo, Schmidt, Marek, Klitsch, Max, Vesely, Stepan, Ploumidis, Achilles, Proietti, Silvia, Kamphuis, Guido, Tokas, Theodore, Geraghty, Rob, and Veneziano, Dominico

Published
2019
Full Text
View/download PDF

7. Supplementary Tables 1-4 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression

Author

Contractor, Kaiyumars, primary, Challapalli, Amarnath, primary, Barwick, Tara, primary, Winkler, Mathias, primary, Hellawell, Giles, primary, Hazell, Steve, primary, Tomasi, Giampaolo, primary, Al-Nahhas, Adil, primary, Mapelli, Paola, primary, Kenny, Laura M., primary, Tadrous, Paul, primary, Coombes, R. Charles, primary, Aboagye, Eric O., primary, and Mangar, Stephen, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 4 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression

Author

Contractor, Kaiyumars, primary, Challapalli, Amarnath, primary, Barwick, Tara, primary, Winkler, Mathias, primary, Hellawell, Giles, primary, Hazell, Steve, primary, Tomasi, Giampaolo, primary, Al-Nahhas, Adil, primary, Mapelli, Paola, primary, Kenny, Laura M., primary, Tadrous, Paul, primary, Coombes, R. Charles, primary, Aboagye, Eric O., primary, and Mangar, Stephen, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 6 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression

Author

Contractor, Kaiyumars, primary, Challapalli, Amarnath, primary, Barwick, Tara, primary, Winkler, Mathias, primary, Hellawell, Giles, primary, Hazell, Steve, primary, Tomasi, Giampaolo, primary, Al-Nahhas, Adil, primary, Mapelli, Paola, primary, Kenny, Laura M., primary, Tadrous, Paul, primary, Coombes, R. Charles, primary, Aboagye, Eric O., primary, and Mangar, Stephen, primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 1 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression

Author

Contractor, Kaiyumars, primary, Challapalli, Amarnath, primary, Barwick, Tara, primary, Winkler, Mathias, primary, Hellawell, Giles, primary, Hazell, Steve, primary, Tomasi, Giampaolo, primary, Al-Nahhas, Adil, primary, Mapelli, Paola, primary, Kenny, Laura M., primary, Tadrous, Paul, primary, Coombes, R. Charles, primary, Aboagye, Eric O., primary, and Mangar, Stephen, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 2 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression

Author

Contractor, Kaiyumars, primary, Challapalli, Amarnath, primary, Barwick, Tara, primary, Winkler, Mathias, primary, Hellawell, Giles, primary, Hazell, Steve, primary, Tomasi, Giampaolo, primary, Al-Nahhas, Adil, primary, Mapelli, Paola, primary, Kenny, Laura M., primary, Tadrous, Paul, primary, Coombes, R. Charles, primary, Aboagye, Eric O., primary, and Mangar, Stephen, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 3 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression

Author

Contractor, Kaiyumars, primary, Challapalli, Amarnath, primary, Barwick, Tara, primary, Winkler, Mathias, primary, Hellawell, Giles, primary, Hazell, Steve, primary, Tomasi, Giampaolo, primary, Al-Nahhas, Adil, primary, Mapelli, Paola, primary, Kenny, Laura M., primary, Tadrous, Paul, primary, Coombes, R. Charles, primary, Aboagye, Eric O., primary, and Mangar, Stephen, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 5 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression

Author

Contractor, Kaiyumars, primary, Challapalli, Amarnath, primary, Barwick, Tara, primary, Winkler, Mathias, primary, Hellawell, Giles, primary, Hazell, Steve, primary, Tomasi, Giampaolo, primary, Al-Nahhas, Adil, primary, Mapelli, Paola, primary, Kenny, Laura M., primary, Tadrous, Paul, primary, Coombes, R. Charles, primary, Aboagye, Eric O., primary, and Mangar, Stephen, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure Legends 1-7 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression

Author

Contractor, Kaiyumars, primary, Challapalli, Amarnath, primary, Barwick, Tara, primary, Winkler, Mathias, primary, Hellawell, Giles, primary, Hazell, Steve, primary, Tomasi, Giampaolo, primary, Al-Nahhas, Adil, primary, Mapelli, Paola, primary, Kenny, Laura M., primary, Tadrous, Paul, primary, Coombes, R. Charles, primary, Aboagye, Eric O., primary, and Mangar, Stephen, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 7 from Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression

Author

Contractor, Kaiyumars, primary, Challapalli, Amarnath, primary, Barwick, Tara, primary, Winkler, Mathias, primary, Hellawell, Giles, primary, Hazell, Steve, primary, Tomasi, Giampaolo, primary, Al-Nahhas, Adil, primary, Mapelli, Paola, primary, Kenny, Laura M., primary, Tadrous, Paul, primary, Coombes, R. Charles, primary, Aboagye, Eric O., primary, and Mangar, Stephen, primary

Published
2023
Full Text
View/download PDF

20. PD34-12 MRI FINDINGS IN DE NOVO SYNCHRONOUS METASTATIC PROSTATE CANCER AND IMPLICATIONS FOR CYTOREDUCTIVE SURGERY

Author

Connor, Martin John, primary, Edison, Marie, additional, Bass, Edward J., additional, Eldred-Evans, David, additional, Bertoncelli, Mariana Tanaka, additional, Hrouda, David, additional, Khoubehi, Bijan, additional, Hellawell, Giles, additional, Rai, Bhavan, additional, Dudderidge, Tim, additional, Tam, Henry, additional, Winkler, Mathias, additional, and Ahmed, Hashim U., additional

Published
2021
Full Text
View/download PDF

21. PD59-10 FACTORS ASSOCIATED WITH HIGH-QUALITY SURGERY FOLLOWING RADICAL CYSTECTOMY: ANALYSIS OF THE BRITISH ASSOCIATION OF UROLOGICAL SURGEONS (BAUS) CYSTECTOMY AUDIT

Author

Tan, Wei Shen, primary, Leow, Jeffrey, additional, Marchese, Maya, additional, Sridhar, Ashwin, additional, Hellawell, Giles, additional, Mossanen, Matthew, additional, Teoh, Jeremy, additional, Fowler, Sarah, additional, Colquhoun, Alexandra, additional, Cresswell, Jo, additional, Catto, James, additional, Trinh, Quoc-Dien, additional, and Kelly, John, additional

Published
2021
Full Text
View/download PDF

24. The IDENTIFY Study: The Investigation and Detection of Urological Neoplasia in Patients Referred with Suspected Urinary Tract Cancer; A multicentre observational study

Author

Khadhouri, Sinan, Gallagher, Kevin M., MacKenzie, Kenneth R., Shah, Taimur T., Gao, Chuanyu, Moore, Sacha, Zimmermann, Eleanor F., Edison, Eric, Jefferies, Matthew, Nambiar, Arjun, Mannas, Miles P., Lee, Taeweon, Marra, Giancarlo, Lillaz, Beatrice, Gómez Rivas, Juan, Olivier, Jonathan, Assmus, Mark A., Uçar, Taha, Claps, Francesco, Boltri, Matteo, Burnhope, Tara, Nkwam, Nkwam, Tanasescu, George, Boxall, Nicholas E., Downey, Alison P., Lal, Asim A, Antón-Juanilla, Marta, Clarke, Holly, Lau, David H. W., Gillams, Kathryn, Crockett, Matthew, Nielsen, Matthew, Takwoingi, Yemisi, Chuchu, Naomi, O'Rourke, John, MacLennan, Graeme, McGrath, John S., Kasivisvanathan, Veeru, Chaudry, Aasem, Sharma, Abhishek, Bennett, Adam, Ahmad, Adnan, Abroaf, Ahmed, Suliman, Ahmed M, Lloyd, Aimee, McKay, Alastair, Wong, Albert, Silva, Alberto, Schneider, Alexandre, MacKay, Alison, Knight, Allen, Grigorakis, Alkiviadis, Bdesha, Amar, Nagle, Amy, Cebola, Ana, Dhanasekaran, Ananda Kumar, Kond?a, Andra?, Barcelos, André, Galosi, Andrea B, Ebur, Andrea, Minervini, Andrea, Russell, Andrew, Webb, Andrew, García de Jalón, Ángel, Desai, Ankit, Czech, Anna K, Mainwaring, Anna, Adimonye, Anthony, Das, Arighno, Figueiredo, Arnaldo, Villers, Arnauld, Leminski, Artur, Chippagiri, Arvinda, Y?ld?r?m, As?f, Voulgaris, Athanasios M, Uzan, Audrey, Oo, Aye Moh Moh, Younis, Ayman, Zelhof, Bachar, Mukhtar, Bashir, Ayres, Ben, Challacombe, Ben, Sherwood, Benedict, Ristau, Benjamin, Lai, Billy, Nellensteijn, Brechtje, Schreiter, Brielle, Trombetta, Carlo, Dowling, Catherine, Hobbs, Catherine, Benitez, Cayo Augusto Estigarribia, Lebacle, Cédric, Ho, Cherrie Wing Yin, Ng, ChiFai, Mount, Chloe, Lam, Chon Meng, Blick, Chris, Brown, Christian, Gallegos, Christopher, Higgs, Claire, Browne, Clíodhna, McCann, Conor, Alonso, Cristina Plaza, Beder, Daniel, Cohen, Daniel, Gordon, Daniel, Wilby, Daniel, Gordon, Danny, Lau, David Hua Wu, Hrouda, David, Karsza, Dávid, Mak, David, Martin-Way, David, Suthaharan, Denula, Patel, Dhruv, Carrion, Diego M, Nyanhongo, Donald, Bass, Edward, Mains, Edward, Chau, Edwin, Castillo, Elba Canelon, Day, Elizabeth, Desouky, Elsayed, Gaines, Emily, Papworth, Emma, Yuruk, Emrah, Kilic, Enes, Dinneen, Eoin, Palagonia, Erika, Xylinas, Evanguelos, Khawaja, Faizan, Cimarra, Fernando, Bardet, Florian, Kum, Francesca, Peters, Francesca, Kovács, Gábor, Tanasescu, Geroge, Hellawell, Giles, Tasso, Giovanni, Lam, Gitte, La Montagna, Giuseppe, Pizzuto, Giuseppe, Lenart, Gordan, Özgür, Günal, Bi, Hai, Lyons, Hannah, Warren, Hannah, Ahmed, Hashim, Simpson, Helen, Burden, Helena, Gresty, Helena, Pita, Hernado Rios, Serag, Hosam, Kynaston, Howard, Crawford-Smith, Hugh, Mostafid, Hugh, Otaola-Arca, Hugo, Fen Koo, Hui, Ibrahim, Ibrahim, Ouzaid, Idir, Puche-Sanz, Ignacio, Tomakovi, Igor, Tinay, Ilker, Sahibzada, Iqbal, Thangasamy, Isaac, Cadena, Iván Revelo, Irani, Jacques, Udzik, Jakub, Brittain, James, Catto, James, Green, James, Tweedle, James, Hernando, Jamie Borrego, Leask, Jamie, Kalsi, Jas, Frankel, Jason, Toniolo, Jason, Raman, Jay D, Courcier, Jean, Kumaradeevan, Jeevan, Clark, Jennifer, Jones, Jennifer, Teoh, Jeremy YuenChun, Iacovou, John, Kelly, John, Selph, John P, Aning, Jonathan, Deeks, Jon, Maw, Jonny, Herranz-Yagüe, José Antonio, Nolazco, Jose Ignacio, Cózar-Olmo, Jose Manuel, Bagley, Joseph, Jelski, Joseph, Norris, Joseph, Testa, Joseph, Meeks, Joshua, Hernandez, Juan, Vásquez, Juan Luis, Randhawa, Karen, Dhera, Karishma, Gronostaj, Katarzyna, Houlton, Kathleen, Lehman, Kathleen, Adasonla, Kelvin, Brown, Kevin, Murtagh, Kevin, Mistry, Kiki, Davenport, Kim, Kitamura, Kosuke, Derbyshire, Laura, Clarke, Laurence, Morton, Lawrie, Martinez, Levin, Goldsmith, Louise, Paramore, Louise, Cormier, Luc, Dell'Atti, Lucio, Simmons, Lucy, Martinez-Piñeiro, Luis, Rico, Luis, Chan, Luke, Forster, Luke, Ma, Lulin, Moore, Madeline, Gallego, Maria Camacho, Freire, Maria José, Emberton, Mark, Feneley, Mark, Rivero, Marta Viridiana Muñoz, Pira, Matea, Tallè, Matteo, Liew, Matthew, Trail, Matthew, Cooper, Meghan, Kulkarni, Meghana, Ager, Michael, He, Ming, Li, Mo, Omran Breish, Mohamed, Tarin, Mohamed, Aldiwani, Mohammed, Matanhelia, Mudit, Pasha, Muhammad, Akaln, Mustafa Kaan, Abdullah, Nasreen, Hale, Nathan, Gadiyar, Neha, Kocher, Neil, Bullock, Nicholas, Campain, Nicholas, Pavan, Nicola, Al?Ibraheem, Nihad, Bhatt, Nikita, Bedi, Nishant, Shrotri, Nitin, Lobo, Niyati, Balderas, Olga, Kouli, Omar, Capoun, Otakar, Manjavacas, Pablo Oteo, Gontero, Paolo, Mariappan, Paramananthan, Marchiñena, Patricio Garcia, Erotocritou, Paul, Sweeney, Paul, Planelles, Paula, Acher, Peter, Black, Peter C, Osei?Bonsu, Peter K, Østergren, Peter, Smith, Peter, Willemse, Peter-Paul Michiel, Chlosta, Piotr L, Ul Ain, Qurrat, Barratt, Rachel, Esler, Rachel, Khalid, Raihan, Hsu, Ray, Stamirowski, Remigiusz, Mangat, Reshma, Cruz, Ricardo, Ellis, Ricky, Adams, Robert, Hessell, Robert, Oomen, Robert J.A., McConkey, Robert, Ritchie, Robert, Jarimba, Roberto, Chahal, Rohit, Andres, Rosado Mario, Hawkins, Rosalyn, David, Rotimi, Manecksha, Rustom P, Agrawal, Sachin, Hamid, Syed Sami, Deem, Samuel, Goonewardene, Sanchia, Swami, Satchi Kuchibhotla, Hori, Satoshi, Khan, Shahid, Inder, Shakeel Mohammud, Sangaralingam, Shanthi, Marathe, Shekhar, Raveenthiran, Sheliyan, Horie, Shigeo, Sengupta, Shomik, Parson, Sian, Parker, Sidney, Hawlina, Simon, Williams, Simon, Mazzoli, Simone, Kata, Slawomir Grzegorz, Lopes, Sofia Pinheiro, Ramos, Sónia, Rai, Sonpreet, Rintoul-Hoad, Sophie, O'Meara, Sorcha, Morris, Steve, Turner, Stacey, Venturini, Stefano, Almpanis, Stephanos, Joniau, Steven, Jain, Sunjay, Mallett, Susan, Nikles, Sven, Yan, Shahzad Sylvia, Drake, Tamsin, Toma, Tarq, Plo, Teresa Cabañuz, Bonnin, Thierry, Muilwijk, Tim, Wollin, Tim, Chu, Timothy Shun Man, Appanna, Timson, Brophy, Tom, Ellul, Tom, Austin, Tomas, Smrkolj, Toma, Rowe, Tracey, Sukhu, Troy, Patel, Trushar, Garg, Tullika, Çakurlu, Turhan, Bele, Uros, Haroon, Usman, Crespo-Atín, Víctor, Cortes, Victor Parejo, Poves, Victoria Capapé, Gnanapragasam, Vincent, Gauhar, Vineet, During, Vinnie, Kumar, Vivek, Fiala, Vojtech, Mahmalji, Wasim, Lam, Wayne, Chin, Yew Fung, Filtekin, Yigit, Phan, Yih Chyn, Ibrahim, Youssed, Glaser, Zachary A, Adwin, Zainal, Qin, Zijian, Zotter, Zsuzsanna, Zainuddin, Zulkifli, Khadhouri, Sinan, Gallagher, Kevin M, Mackenzie, Kenneth R, Shah, Taimur T, Gao, Chuanyu, Moore, Sacha, Zimmermann, Eleanor F, Edison, Eric, Jefferies, Matthew, Nambiar, Arjun, Mannas, Miles P, Lee, Taeweon, Marra, Giancarlo, Lillaz, Beatrice, Gómez Rivas, Juan, Olivier, Jonathan, Assmus, Mark A, Uçar, Taha, Claps, Francesco, Boltri, Matteo, Burnhope, Tara, Nkwam, Nkwam, Tanasescu, George, Boxall, Nicholas E, Downey, Alison P, Lal, Asim Ahmed, Antón-Juanilla, Marta, Clarke, Holly, Hw Lau, David, Gillams, Kathryn, Crockett, Matthew, Nielsen, Matthew, Takwoingi, Yemisi, Chuchu, Naomi, O'Rourke, John, Maclennan, Graeme, Mcgrath, John S, Kasivisvanathan, Veeru, Khadhouri, Sinan [0000-0002-1836-8992], Moore, Sacha [0000-0002-0914-2051], Gómez Rivas, Juan [0000-0002-0556-3035], Olivier, Jonathan [0000-0002-5409-2911], Assmus, Mark A [0000-0003-3615-9251], Claps, Francesco [0000-0003-2812-5553], Nkwam, Nkwam [0000-0003-1086-6388], and Apollo - University of Cambridge Repository

Subjects
Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, Male, =+16+years%2C+referred+to+secondary+care+with+suspected+urinary+tract+cancer%2E+Patients+with+a+known+or+previous+urological+malignancy+were+excluded%2E+We+estimated+the+prevalence+of+bladder+cancer%2C+UTUC%2C+renal+cancer+and+prostate+cancer%22">Objective To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. Patients and Methods This was an international multicentre prospective observational study. We included patients aged >= 16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer, stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. Results Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05, P < 0.001), visible haematuria 3.47 (95% CI 2.90-4.15, P < 0.001), male sex 1.30 (95% CI 1.14-1.50, P < 0.001), and smoking 2.70 (95% CI 2.30-3.18, P < 0.001). Conclusions A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer, renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), bladder cancer, cancer prevalence, haematuria, hematuria, prostate cancer, renal cancer, upper tract urothelial cancer, urinary tract cancer, Adult, Aged, Female, Hematuria, Humans, Kidney Neoplasms, Middle Aged, Prospective Studies, Referral and Consultation, Ureteral Neoplasms, Urinary Bladder Neoplasms, Disease, urologic and male genital diseases, Prostate cancer, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, =+16+years%22">adjusted for established patient risk markers and geographical variation. Patients and Methods This was an international multicentre prospective observational study. We included patients aged >= 16 years, Medicine, bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, education.field_of_study, and smoking 2.70 (95% CI 2.30-3.18, stratified by age, female genital diseases and pregnancy complications, renal cancer and prostate cancer, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer, age 1.04 (95% CI 1.03-1.05 [stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. Results Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were], UTUC (n = 128) 1.14% (95% CI 0.77-1.52), 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), visible haematuria 3.47 (95% CI 2.90-4.15, type of haematuria, P < 0.001), medicine.medical_specialty, Urology, Urinary system, Population, and countries. Results Of the 11 059 patients assessed for eligibility, Malignancy, smoking, UTUC, Internal medicine, sex, education, Bladder cancer, and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05, business.industry, Cancer, Odds ratio, medicine.disease, male sex 1.30 (95% CI 1.14-1.50, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, P < 0.001). Conclusions A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, hospitals, business
Abstract

Funder: Action Bladder Cancer UK, Funder: Rosetrees Trust; Id: http://dx.doi.org/10.13039/501100000833, Funder: Urology Care Foundation; Id: http://dx.doi.org/10.13039/100006280, OBJECTIVE: To evaluate the contemporary prevalence of urinary tract cancer (bladder cancer, upper tract urothelial cancer [UTUC] and renal cancer) in patients referred to secondary care with haematuria, adjusted for established patient risk markers and geographical variation. PATIENTS AND METHODS: This was an international multicentre prospective observational study. We included patients aged ≥16 years, referred to secondary care with suspected urinary tract cancer. Patients with a known or previous urological malignancy were excluded. We estimated the prevalence of bladder cancer, UTUC, renal cancer and prostate cancer; stratified by age, type of haematuria, sex, and smoking. We used a multivariable mixed-effects logistic regression to adjust cancer prevalence for age, type of haematuria, sex, smoking, hospitals, and countries. RESULTS: Of the 11 059 patients assessed for eligibility, 10 896 were included from 110 hospitals across 26 countries. The overall adjusted cancer prevalence (n = 2257) was 28.2% (95% confidence interval [CI] 22.3-34.1), bladder cancer (n = 1951) 24.7% (95% CI 19.1-30.2), UTUC (n = 128) 1.14% (95% CI 0.77-1.52), renal cancer (n = 107) 1.05% (95% CI 0.80-1.29), and prostate cancer (n = 124) 1.75% (95% CI 1.32-2.18). The odds ratios for patient risk markers in the model for all cancers were: age 1.04 (95% CI 1.03-1.05; P < 0.001), visible haematuria 3.47 (95% CI 2.90-4.15; P < 0.001), male sex 1.30 (95% CI 1.14-1.50; P < 0.001), and smoking 2.70 (95% CI 2.30-3.18; P < 0.001). CONCLUSIONS: A better understanding of cancer prevalence across an international population is required to inform clinical guidelines. We are the first to report urinary tract cancer prevalence across an international population in patients referred to secondary care, adjusted for patient risk markers and geographical variation. Bladder cancer was the most prevalent disease. Visible haematuria was the strongest predictor for urinary tract cancer.

Published
2021
Full Text
View/download PDF

25. Does urinary cytology have a role in haematuria investigations?

Author

Tan, Wei Shen, Sarpong, Rachael, Khetrapal, Pramit, Rodney, Simon, Mostafid, Hugh, Cresswell, Joanne, Watson, Dawn, Rane, Abhay, Hicks, James, Hellawell, Giles, Davies, Melissa, Srirangam, Shalom J., Dawson, Louise, Payne, David, Williams, Norman, Brew‐Graves, Chris, Feber, Andrew, and Kelly, John D.

Subjects
Male, Urological Oncology, diagnosis, Urine, urologic and male genital diseases, #blcsm, Predictive Value of Tests, Humans, False Positive Reactions, Prospective Studies, False Negative Reactions, Aged, Hematuria, Neoplasm Staging, Ultrasonography, Carcinoma, Transitional Cell, Ureteral Neoplasms, #BladderCancer, Urography, Middle Aged, Kidney Neoplasms, haematuria, investigations, Urinary Bladder Neoplasms, #utuc, cytology, biomarker, Female, Neoplasm Grading, Tomography, X-Ray Computed
Abstract

Objectives To determine the diagnostic accuracy of urinary cytology to diagnose bladder cancer and upper tract urothelial cancer (UTUC) as well as the outcome of patients with a positive urine cytology and normal haematuria investigations in patients in a multicentre prospective observational study of patients investigated for haematuria. Patient and methods The DETECT I study (clinicaltrials.gov NCT02676180) recruited patients presenting with haematuria following referral to secondary case at 40 hospitals. All patients had a cystoscopy and upper tract imaging (renal bladder ultrasound [RBUS] and/ or CT urogram [CTU]). Patients, where urine cytology were performed, were sub‐analysed. The reference standard for the diagnosis of bladder cancer and UTUC was histological confirmation of cancer. A positive urine cytology was defined as a urine cytology suspicious for neoplastic cells or atypical cells. Results Of the 3 556 patients recruited, urine cytology was performed in 567 (15.9%) patients from nine hospitals. Median time between positive urine cytology and endoscopic tumour resection was 27 (IQR: 21.3–33.8) days. Bladder cancer was diagnosed in 39 (6.9%) patients and UTUC in 8 (1.4%) patients. The accuracy of urinary cytology for the diagnosis of bladder cancer and UTUC was: sensitivity 43.5%, specificity 95.7%, positive predictive value (PPV) 47.6% and negative predictive value (NPV) 94.9%. A total of 21 bladder cancers and 5 UTUC were missed. Bladder cancers missed according to grade and stage were as follows: 4 (19%) were ≥ pT2, 2 (9.5%) were G3 pT1, 10 (47.6%) were G3/2 pTa and 5 (23.8%) were G1 pTa. High‐risk cancer was confirmed in 8 (38%) patients. There was a marginal improvement in sensitivity (57.7%) for high‐risk cancers. When urine cytology was combined with imaging, the diagnostic performance improved with CTU (sensitivity 90.2%, specificity 94.9%) superior to RBUS (sensitivity 66.7%, specificity 96.7%). False positive cytology results were confirmed in 22 patients, of which 12 (54.5%) had further invasive tests and 5 (22.7%) had a repeat cytology. No cancer was identified in these patients during follow‐up. Conclusions Urine cytology will miss a significant number of muscle‐invasive bladder cancer and high‐risk disease. Our results suggest that urine cytology should not be routinely performed as part of haematuria investigations. The role of urine cytology in select cases should be considered in the context of the impact of a false positive result leading to further potentially invasive tests conducted under general anaesthesia.

Published
2018

29. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial

Author

Connor, Martin John, primary, Shah, Taimur Tariq, additional, Smigielska, Katarzyna, additional, Day, Emily, additional, Sukumar, Johanna, additional, Fiorentino, Francesca, additional, Sarwar, Naveed, additional, Gonzalez, Michael, additional, Falconer, Alison, additional, Klimowska-Nassar, Natalia, additional, Evans, Martin, additional, Naismith, Olivia Frances, additional, Thippu Jayaprakash, Kamalram, additional, Price, Derek, additional, Gayadeen, Shiva, additional, Basak, Dolan, additional, Horan, Gail, additional, McGrath, John, additional, Sheehan, Denise, additional, Kumar, Manal, additional, Ibrahim, Azman, additional, Brock, Cathryn, additional, Pearson, Rachel A., additional, Anyamene, Nicola, additional, Heath, Catherine, additional, Shergill, Iqbal, additional, Rai, Bhavan, additional, Hellawell, Giles, additional, McCracken, Stuart, additional, Khoubehi, Bijan, additional, Mangar, Stephen, additional, Khoo, Vincent, additional, Dudderidge, Tim, additional, Staffurth, John Nicholas, additional, Winkler, Mathias, additional, and Ahmed, Hashim Uddin, additional

Published
2021
Full Text
View/download PDF

30. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis

Author

Kasivisvanathan, Veeru, Rannikko, Antti S, Borghi, Marcelo, Panebianco, Valeria, Mynderse, Lance A, Vaarala, Markku H, Briganti, Alberto, Budäus, Lars, Hellawell, Giles, Hindley, Richard G, Roobol, Monique J, Eggener, Scott, Ghei, Maneesh, Villers, Arnauld, Bladou, Franck, Villeirs, Geert M, Virdi, Jaspal, Boxler, Silvan, Robert, Grégoire, Singh, Paras B, Venderink, Wulphert, Hadaschik, Boris A, Ruffion, Alain, Jim C, Hu, Margolis, Daniel, Crouzet, Sébastien, Klotz, Laurence, Taneja, Samir S, Pinto, Peter, Gill, Inderbir, Allen, Clare, Giganti, Francesco, Freeman, Alex, Morris, Stephen, Punwani, Shonit, Williams, Norman R, Brew-Graves, Chris, Deeks, Jonathan, Takwoingi, Yemisi, Emberton, Mark, Moore, Caroline M, Precision, Study Group Collaborators, Catalano, Carlo, Leonardo, Costantino, Sciarra, Alessandro, Grompone, Marcello Domenico, Del Monte, Maurizio, D'Eramo, Giuseppe, Salvo, Vincenzo, Campa, Riccardo, Urology, Kasivisvanathan, V., Rannikko, A. S., Borghi, M., Panebianco, V., Mynderse, L. A., Vaarala, M. H., Briganti, A., Budäus, L., Hellawell, G., Hindley, R. G., Roobol, M. J., Eggener, S., Ghei, M., Villers, A., Bladou, F., Villeirs, G. M., Virdi, J., Boxler, S., Robert, G., Singh, P. B., Venderink, W., Hadaschik, B. A., Ruffion, A., Hu, J. C., Margolis, D., Crouzet, S., Klotz, L., Taneja, S. S., Pinto, P., Gill, I., Allen, C., Giganti, F., Freeman, A., Morris, S., Punwani, S., Williams, N. R., Brew-Graves, C., Deeks, J., Takwoingi, Y., Emberton, M., Moore, C. M., and for the PRECISION Study Group, Collaborators

Subjects
Male, fusion, Intention to Treat Analysi, Cost effectiveness, Biopsy, 030232 urology & nephrology, Medizin, outcomes, Prostate cancer, 0302 clinical medicine, Surveys and Questionnaire, 610 Medicine & health, medicine.diagnostic_test, Medicine (all), Prostate, magnetic-resonance, General Medicine, Middle Aged, Magnetic Resonance Imaging, PI-RADS, 030220 oncology & carcinogenesis, Urological cancers Radboud Institute for Health Sciences [Radboudumc 15], Radiology, Human, Quality Control, medicine.medical_specialty, men, Risk Assessment, ultrasound-guided biopsy, active surveillance, cost-effectiveness, Follow-Up Studie, 03 medical and health sciences, All institutes and research themes of the Radboud University Medical Center, SDG 3 - Good Health and Well-being, Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15], medicine, Ultrasonography, Interventional, Aged, Intention-to-treat analysis, business.industry, Cancer, Magnetic resonance imaging, medicine.disease, Prostatic Neoplasm, Quality of Life, Ultrasound-Guided Biopsy, business
Abstract

BACKGROUND: Multiparametric magnetic resonance imaging (MRI), with or without targeted biopsy, is an alternative to standard transrectal ultrasonography-guided biopsy for prostate-cancer detection in men with a raised prostate-specific antigen level who have not undergone biopsy. However, comparative evidence is limited. METHODS: In a multicenter, randomized, noninferiority trial, we assigned men with a clinical suspicion of prostate cancer who had not undergone biopsy previously to undergo MRI, with or without targeted biopsy, or standard transrectal ultrasonography-guided biopsy. Men in the MRI-targeted biopsy group underwent a targeted biopsy (without standard biopsy cores) if the MRI was suggestive of prostate cancer; men whose MRI results were not suggestive of prostate cancer were not offered biopsy. Standard biopsy was a 10-to-12-core, transrectal ultrasonography-guided biopsy. The primary outcome was the proportion of men who received a diagnosis of clinically significant cancer. Secondary outcomes included the proportion of men who received a diagnosis of clinically insignificant cancer. RESULTS: A total of 500 men underwent randomization. In the MRI-targeted biopsy group, 71 of 252 men (28%) had MRI results that were not suggestive of prostate cancer, so they did not undergo biopsy. Clinically significant cancer was detected in 95 men (38%) in the MRI-targeted biopsy group, as compared with 64 of 248 (26%) in the standard-biopsy group (adjusted difference, 12 percentage points; 95% confidence interval [CI], 4 to 20; P = 0.005). MRI, with or without targeted biopsy, was noninferior to standard biopsy, and the 95% confidence interval indicated the superiority of this strategy over standard biopsy. Fewer men in the MRI-targeted biopsy group than in the standard-biopsy group received a diagnosis of clinically insignificant cancer (adjusted difference, -13 percentage points; 95% CI, -19 to -7; P

Published
2018

35. Extended Lateral Pelvic Sidewall Excision [Elsie] for Locally Advanced & Recurrent Rectal Cancer Involving the Lateral Pelvic Sidewall – An Evaluation of a Novel Technique and Its Outcomes

Author

Pring, Edward, primary, Gould, Laura, additional, Fletcher, Jordan, additional, Taylor, Claire, additional, Hona, Therese, additional, Corr, Alison, additional, Burling, David, additional, Hellawell, Giles, additional, Aston, Will, additional, Antoniou, Anthony, additional, and Jenkins, John T., additional

Published
2020
Full Text
View/download PDF

37. Performance Improvement (Pi) score: an algorithm to score Pi objectively during E-BLUS hands-on training sessions. A European Association of Urology, Section of Uro-Technology (ESUT) project

Author

Veneziano, Domenico, primary, Canova, Antonio, additional, Arnolds, Michiel, additional, Beatty, John D., additional, Biyani, Chandra S., additional, Dehò, Federico, additional, Fiori, Cristian, additional, Hellawell, Giles O., additional, Langenhuijsen, J.F., additional, Pini, Giovannalberto, additional, Rodriguez Faba, Oscar, additional, Siena, Giampaolo, additional, Skolarikos, Andreas, additional, Tokas, Theodoros, additional, Van Cleynenbreugel, Ben S.E.P., additional, Wagner, Christian, additional, Tripepi, Giovanni, additional, Somani, Bhaskar, additional, and Lima, Estevao, additional

Published
2018
Full Text
View/download PDF

38. MP77-15 A MULTI-CENTRE RANDOMISED CONTROLLED TRIAL ASSESSING WHETHER MRI-TARGETED BIOPSY IS NON-INFERIOR TO STANDARD TRANS-RECTAL ULTRASOUND GUIDED BIOPSY FOR THE DIAGNOSIS OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WITHOUT PRIOR BIOPSY - THE PRECISION STUDY: PROSTATE EVALUATION FOR CLINICALLY IMPORTANT DISEASE, SAMPLING USING IMAGE-GUIDANCE OR NOT? (NCT02380027)

Author

Kasivisvanathan, Veeru, primary, Rannikko, Antti, additional, Borghi, Marcelo, additional, Panebianco, Valeria, additional, Mynderse, Lance, additional, Vaarala, Markku, additional, Briganti, Alberto, additional, Budäus, Lars, additional, Hellawell, Giles, additional, Hindley, Richard, additional, Roobol, Monique, additional, Eggener, Scott, additional, Ghei, Maneesh, additional, Villers, Arnauld, additional, Bladou, Franck, additional, Villeirs, Geert, additional, Virdi, Jaspal, additional, Boxler, Silvan, additional, Robert, Grégoire, additional, Singh, Paras, additional, Venderink, Wulphert, additional, Hadaschik, Boris, additional, Ruffion, Alain, additional, Hu, Jim, additional, Margolis, Daniel, additional, Crouzet, Sébastien, additional, Klotz, Laurence, additional, Taneja, Samir, additional, Pinto, Peter, additional, Gill, Inderbir, additional, Allen, Clare, additional, Giganti, Francesco, additional, Freeman, Alex, additional, Morris, Steve, additional, Punwani, Shonit, additional, Williams, Norman, additional, Brew-Graves, Chris, additional, Takwoingi, Yemisi, additional, Emberton, Mark, additional, and Moore, Caroline, additional

Published
2018
Full Text
View/download PDF

39. Performance Improvement (Pi) score: an algorithm to score Pi objectively during E‐BLUS hands‐on training sessions. A European Association of Urology, Section of Uro‐Technology (ESUT) project.

Author

Veneziano, Domenico, Fiori, Cristian, Hellawell, Giles O., Langenhuijsen, J.F., Pini, Giovannalberto, Rodriguez Faba, Oscar, Siena, Giampaolo, Skolarikos, Andreas, Tokas, Theodoros, Van Cleynenbreugel, Ben S.E.P., Wagner, Christian, Lima, Bhaskar, Tripepi, Giovanni, Somani, Bhaskar, Canova, Antonio, Arnolds, Michiel, Beatty, John D., Biyani, Chandra S., and Dehò, Federico

Subjects
MEASUREMENT errors, ALGORITHMS, TALLIES
Abstract

Objective: To evaluate the variability of subjective tutor performance improvement (Pi) assessment and to compare it with a novel measurement algorithm: the Pi score. Materials and Methods: The Pi‐score algorithm considers time measurement and number of errors from two different repetitions (first and fifth) of the same training task and compares them to the relative task goals, to produce an objective score. We collected data during eight courses on the four European Association of Urology training in Basic Laparoscopic Urological Skills (E‐BLUS) tasks. The same tutor instructed on all courses. Collected data were independently analysed by 14 hands‐on training experts for Pi assessment. Their subjective Pi assessments were compared for inter‐rater reliability. The average per‐participant subjective scores from all 14 proctors were then compared with the objective Pi‐score algorithm results. Cohen's κ statistic was used for comparison analysis. Results: A total of 50 participants were enrolled. Concordance found between the 14 proctors' scores was the following: Task 1, κ = 0.42 (moderate); Task 2, κ = 0.27 (fair); Task 3, κ = 0.32 (fair); and Task 4, κ = 0.55 (moderate). Concordance between Pi‐score results and proctor average scores per participant was the following: Task 1, κ = 0.85 (almost perfect); Task 2, κ = 0.46 (moderate); Task 3, κ = 0.92 (almost perfect); Task 4 = 0.65 (substantial). Conclusion: The present study shows that evaluation of Pi is highly variable, even when formulated by a cohort of experts. Our algorithm successfully provided an objective score that was equal to the average Pi assessment of a cohort of experts, in relation to a small amount of training attempts. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

40. Does urinary cytology have a role in haematuria investigations?

Author

Tan, Wei Shen, Sarpong, Rachael, Khetrapal, Pramit, Rodney, Simon, Mostafid, Hugh, Cresswell, Joanne, Watson, Dawn, Rane, Abhay, Hicks, James, Hellawell, Giles, Davies, Melissa, Srirangam, Shalom J., Dawson, Louise, Payne, David, Williams, Norman, Brew‐Graves, Chris, Feber, Andrew, Kelly, John D., Sridhar, AN, and Lamb, BW

Subjects
URINARY tract infections, HEMATURIA, BLADDER cancer, UROLOGY, URINARY organs
Abstract

Objectives: To determine the diagnostic accuracy of urinary cytology to diagnose bladder cancer and upper tract urothelial cancer (UTUC) as well as the outcome of patients with a positive urine cytology and normal haematuria investigations in patients in a multicentre prospective observational study of patients investigated for haematuria. Patient and methods: The DETECT I study (clinicaltrials.gov NCT02676180) recruited patients presenting with haematuria following referral to secondary case at 40 hospitals. All patients had a cystoscopy and upper tract imaging (renal bladder ultrasound [RBUS] and/ or CT urogram [CTU]). Patients, where urine cytology were performed, were sub‐analysed. The reference standard for the diagnosis of bladder cancer and UTUC was histological confirmation of cancer. A positive urine cytology was defined as a urine cytology suspicious for neoplastic cells or atypical cells. Results: Of the 3 556 patients recruited, urine cytology was performed in 567 (15.9%) patients from nine hospitals. Median time between positive urine cytology and endoscopic tumour resection was 27 (IQR: 21.3–33.8) days. Bladder cancer was diagnosed in 39 (6.9%) patients and UTUC in 8 (1.4%) patients. The accuracy of urinary cytology for the diagnosis of bladder cancer and UTUC was: sensitivity 43.5%, specificity 95.7%, positive predictive value (PPV) 47.6% and negative predictive value (NPV) 94.9%. A total of 21 bladder cancers and 5 UTUC were missed. Bladder cancers missed according to grade and stage were as follows: 4 (19%) were ≥ pT2, 2 (9.5%) were G3 pT1, 10 (47.6%) were G3/2 pTa and 5 (23.8%) were G1 pTa. High‐risk cancer was confirmed in 8 (38%) patients. There was a marginal improvement in sensitivity (57.7%) for high‐risk cancers. When urine cytology was combined with imaging, the diagnostic performance improved with CTU (sensitivity 90.2%, specificity 94.9%) superior to RBUS (sensitivity 66.7%, specificity 96.7%). False positive cytology results were confirmed in 22 patients, of which 12 (54.5%) had further invasive tests and 5 (22.7%) had a repeat cytology. No cancer was identified in these patients during follow‐up. Conclusions: Urine cytology will miss a significant number of muscle‐invasive bladder cancer and high‐risk disease. Our results suggest that urine cytology should not be routinely performed as part of haematuria investigations. The role of urine cytology in select cases should be considered in the context of the impact of a false positive result leading to further potentially invasive tests conducted under general anaesthesia. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

47. Use of [11C]Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression

Author

Contractor, Kaiyumars, primary, Challapalli, Amarnath, additional, Barwick, Tara, additional, Winkler, Mathias, additional, Hellawell, Giles, additional, Hazell, Steve, additional, Tomasi, Giampaolo, additional, Al-Nahhas, Adil, additional, Mapelli, Paola, additional, Kenny, Laura M., additional, Tadrous, Paul, additional, Coombes, R. Charles, additional, Aboagye, Eric O., additional, and Mangar, Stephen, additional

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results